Jazz Pharmaceuticals (NASDAQ:JAZZ) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii).
CorMedix (NASDAQ:CRMD) announced positive topline results on Monday from the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for the prevention of invasive fungal diseases in adult allogeneic hematopoietic stem cell transplant (HSCT) patients.
Alterity Therapeutics (NASDAQ:ATHE) announced on Monday that it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a second Type C meeting regarding its ATH434 Phase 3 program.
Intellia Therapeutics (NASDAQ:NTLA) today announced positive topline results from its pivotal Phase 3 HAELO clinical trial evaluating lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR-based gene editing therapy for patients with hereditary angioedema (HAE).
Purple Biotech (NASDAQ:PPBT) released promising preclinical data on Monday for its lead therapeutic candidate, IM1240, demonstrating consistent anti-tumor activity across seven distinct patient-derived tumor samples.
HBT Financial (NASDAQ:HBT) reported its first-quarter 2026 financial results on Monday, highlighting a transformative period following the completion of its acquisition of CNB Bank shares.
Lakeland Financial (NASDAQ:LKFN), the parent company of Lake City Bank, reported record-breaking financial results for the first quarter of 2026 on Monday.
Alliance Resource Partners (NASDAQ:ARLP) reported its financial and operating results for the first quarter of 2026 on Monday, characterized by record-breaking performance in its royalty segments despite pricing challenges in the coal market.
SCHMID Group (NASDAQ:SHMD) released its first-quarter operational metrics for 2026 on Monday, reporting total revenues of €18.2 million.
Granite (NYSE:GVA) announced on Monday the completion of its acquisition of Kenny Seng Construction, a strategic move aimed at solidifying the company's vertically integrated construction and materials platform in Utah.
Eli Lilly (NYSE:LLY) has reached a definitive agreement to acquire Ajax Therapeutics, a biotechnology firm specializing in next-generation therapies for myeloproliferative neoplasms (MPNs).
The U.S. Food and Drug Administration has approved AstraZeneca’s (NASDAQ:AZN) Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector, the Saphnelo Pen.
